LAG3 and metastatic melanoma: For details, in 2022, the U.S. FDA approved the combination therapy of relatlimab and nivolumab for adults and children 12 years of age and older with unresectable or metastatic melanoma, setting the milestone for the application of LAG-3 inhibitors, as a novel ICI, in cancer treatment [78].